Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι.

Sajan MP, Nimal S, Mastorides S, Acevedo-Duncan M, Kahn CR, Fields AP, Braun U, Leitges M, Farese RV.

Metabolism. 2012 Apr;61(4):459-69. doi: 10.1016/j.metabol.2011.12.008. Epub 2012 Jan 5.


Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes.

Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR Jr, Nimal S, Choi CS, Kim S, Shulman GI, Kahn CR, Braun U, Leitges M.

J Clin Invest. 2007 Aug;117(8):2289-301. Erratum in: J Clin Invest. 2007 Oct;117(10):3141.


The critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity.

Sajan MP, Standaert ML, Nimal S, Varanasi U, Pastoor T, Mastorides S, Braun U, Leitges M, Farese RV.

J Lipid Res. 2009 Jun;50(6):1133-45. doi: 10.1194/jlr.M800520-JLR200. Epub 2009 Feb 6.


Atypical protein kinase C in cardiometabolic abnormalities.

Farese RV, Sajan MP.

Curr Opin Lipidol. 2012 Jun;23(3):175-81. doi: 10.1097/MOL.0b013e328352c4c7. Review.


Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.

Sajan MP, Ivey RA, Lee MC, Farese RV.

J Lipid Res. 2015 Jan;56(1):70-80. doi: 10.1194/jlr.M052977. Epub 2014 Nov 13.


PKCλ haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes.

Sajan MP, Ivey RA 3rd, Lee M, Mastorides S, Jurczak MJ, Samuels VT, Shulman GI, Braun U, Leitges M, Farese RV.

Mol Endocrinol. 2014 Jul;28(7):1097-107. doi: 10.1210/me.2014-1025. Epub 2014 May 30.


Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.

Farese RV, Sajan MP, Standaert ML.

Exp Biol Med (Maywood). 2005 Oct;230(9):593-605. Review.


Atypical PKC: a target for treating insulin-resistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus.

Farese RV, Lee MC, Sajan MP.

Expert Opin Ther Targets. 2014 Oct;18(10):1163-75. Review.


Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.

Sajan MP, Standaert ML, Rivas J, Miura A, Kanoh Y, Soto J, Taniguchi CM, Kahn CR, Farese RV.

Diabetologia. 2009 Jun;52(6):1197-207. doi: 10.1007/s00125-009-1336-5. Epub 2009 Apr 9.


AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC.

Sajan MP, Bandyopadhyay G, Miura A, Standaert ML, Nimal S, Longnus SL, Van Obberghen E, Hainault I, Foufelle F, Kahn R, Braun U, Leitges M, Farese RV.

Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E179-92. doi: 10.1152/ajpendo.00392.2009. Epub 2009 Nov 3.


Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity.

Sajan MP, Acevedo-Duncan ME, Standaert ML, Ivey RA, Lee M, Farese RV.

Diabetes. 2014 Aug;63(8):2690-701. doi: 10.2337/db13-1863. Epub 2014 Apr 4.


Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota.

Standaert ML, Ortmeyer HK, Sajan MP, Kanoh Y, Bandyopadhyay G, Hansen BC, Farese RV.

Diabetes. 2002 Oct;51(10):2936-43.


Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status.

Farese RV, Sajan MP.

Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E385-94. doi: 10.1152/ajpendo.00608.2009. Epub 2009 Dec 8. Review.


Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.

Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV.

Diabetes. 2003 Aug;52(8):1926-34.


Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.

Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV.

Diabetologia. 2006 Feb;49(2):375-82. Epub 2006 Jan 5.


Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans.

Casaubon L, Sajan MP, Rivas J, Powe JL, Standaert ML, Farese RV.

Diabetologia. 2006 Dec;49(12):3000-8. Epub 2006 Oct 7.


Tissue-specific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver, and adipocytes of insulin receptor substrate-1 knockout mice.

Sajan MP, Standaert ML, Miura A, Kahn CR, Farese RV.

Mol Endocrinol. 2004 Oct;18(10):2513-21. Epub 2004 Jul 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk